MCID: ANX010
MIFTS: 72

Anxiety

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Anxiety

MalaCards integrated aliases for Anxiety:

Name: Anxiety 57 12 29 6 43 40 73
Anxiety Disorders 55 44 73
Anxiety Disorder 12 15
Anxiety State 12 73
Anxiety Neurosis 73

Classifications:



External Ids:

OMIM 57 607834
Disease Ontology 12 DOID:2030
ICD10 33 F41.9 F41.8
MeSH 44 D001008
NCIt 50 C2878
SNOMED-CT 68 65673007
MedGen 42 C0003467

Summaries for Anxiety

OMIM : 57 Human personality is shaped by genetic and environmental factors, and evidence suggests that the genetic component is highly complex, polygenic, and epistatic. Genetic factors are thought to contribute to 40 to 60% of trait variance. Molecular genetics has tried to identify specific genes for quantitative traits, called quantitative trait loci (QTLs). The QTL concept suggests that complex personality traits or dimensions are not attributable to single genes, but to multiple interacting genes (Reif and Lesch, 2003). Fullerton et al. (2003) stated that psychologists were in agreement that the wide variation in human personalities can be explained by a small number of personality factors, including neuroticism (a measure of emotional stability), which manifests at one extreme as anxiety, depression, moodiness, low self-esteem, and diffidence. They cited a number of studies that had described a relationship between high scores on measures of neuroticism and major depressive disorder. They also noted that theoretical studies had suggested that large samples of randomly ascertained sibs could be used to ascertain phenotypically extreme individuals and thereby increase power to detect genetic linkage in complex traits. See also panic disorder (PAND1; 167870), which is a subtype of anxiety disorder. (607834)

MalaCards based summary : Anxiety, also known as anxiety disorders, is related to generalized anxiety disorder and social phobia, and has symptoms including agitation, nervousness and sleeplessness. An important gene associated with Anxiety is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Alprazolam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

MedlinePlus : 43 Fear and anxiety are part of life. You may feel anxious before you take a test or walk down a dark street. This kind of anxiety is useful - it can make you more alert or careful. It usually ends soon after you are out of the situation that caused it. But for millions of people in the United States, the anxiety does not go away, and gets worse over time. They may have chest pains or nightmares. They may even be afraid to leave home. These people have anxiety disorders. Types include Panic disorder Obsessive-compulsive disorder Post-traumatic stress disorder Phobias Generalized anxiety disorder Treatment can involve medicines, therapy or both. NIH: National Institute of Mental Health

Wikipedia : 76 Anxiety is an emotion characterized by an unpleasant state of inner turmoil, often accompanied by... more...

Related Diseases for Anxiety

Diseases related to Anxiety via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 723)
# Related Disease Score Top Affiliating Genes
1 generalized anxiety disorder 33.9 BDNF COMT CRHR1 HTR1A HTR2A MAOA
2 social phobia 33.3 HTR1A MAOA SLC6A4
3 phobic disorder 33.1 COMT HTR1A MAOA PTK7 SLC6A4
4 agoraphobia 32.6 CCKBR HTR1A MAOA PTK7 SLC6A4
5 phobia, specific 32.4 COMT MAOA
6 panic disorder 32.3 BDNF CCKBR COMT CRH CRHR1 HTR1A
7 avoidant personality disorder 32.1 MAOA SLC6A4 TPH1
8 autism spectrum disorder 32.0 BDNF HTR2A SLC6A4 TPH2
9 fibromyalgia 32.0 COMT CRH HTR2A SLC6A4
10 irritable bowel syndrome 32.0 CRH CRHR1 SLC6A4 TPH1
11 bulimia nervosa 32.0 BDNF COMT HTR2A SLC6A4
12 postpartum depression 32.0 BDNF COMT CRH MAOA SLC6A4
13 eating disorder 32.0 BDNF CNR1 COMT CRH HTR2C SLC6A4
14 obsessive-compulsive disorder 31.8 BDNF COMT CRH CYP2D6 HTR1A HTR2A
15 dependent personality disorder 31.7 CYP3A4 MAOA
16 post-traumatic stress disorder 31.7 BDNF CNR1 COMT CRH HTR2A MAOA
17 migraine with or without aura 1 31.6 CNR1 COMT CYP2D6 HTR1A HTR2A HTR2C
18 parkinson disease, late-onset 31.6 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
19 bipolar disorder 31.4 BDNF COMT CRH HTR1A HTR2A HTR2C
20 schizophrenia 31.4 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
21 depression 31.2 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
22 alexithymia 30.9 COMT HTR1A SLC6A4
23 autism 30.7 BDNF COMT HTR1A HTR2A MAOA SLC6A4
24 anorexia nervosa 30.6 BDNF COMT CRH HTR2A SLC6A4
25 personality disorder 30.6 BDNF COMT HTR1A HTR2A HTR2C MAOA
26 alcohol abuse 30.5 BDNF CNR1 HTR2A SLC6A4
27 conduct disorder 30.4 COMT MAOA SLC6A4 TPH1
28 dysthymic disorder 30.4 HTR2A MAOA SLC6A4
29 oppositional defiant disorder 30.4 COMT MAOA SLC6A4 TPH2
30 substance abuse 30.3 BDNF COMT CYP2D6 MAOA SLC6A4
31 tobacco addiction 30.3 COMT HTR2A MAOA SLC6A4 TPH1
32 premature ejaculation 30.2 COMT HTR1A HTR2C SLC6A4
33 antisocial personality disorder 30.2 COMT MAOA SLC6A4
34 mood disorder 30.1 BDNF COMT CRH CRHR1 HTR1A HTR2A
35 bipolar i disorder 30.1 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
36 drug dependence 30.1 BDNF CNR1 CRH SLC6A4
37 attention deficit-hyperactivity disorder 30.1 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
38 major depressive disorder 30.0 BDNF COMT CRH CRHR1 CYP2D6 HTR1A
39 pathological gambling 29.9 HTR2A MAOA SLC6A4
40 psychotic disorder 29.9 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
41 schizoaffective disorder 29.9 BDNF COMT HTR2A SLC6A4
42 alcohol dependence 29.8 BDNF CNR1 COMT CRHR1 HTR1A HTR2A
43 atypical depressive disorder 29.8 CRH HTR2A MAOA SLC6A4
44 substance dependence 29.8 BDNF CNR1 CYP2D6 MAOA SLC6A4
45 borderline personality disorder 29.7 BDNF COMT HTR1A HTR2A HTR2C MAOA
46 chronic fatigue syndrome 29.7 COMT CRH HTR1A HTR2A MAOA NR3C1
47 endogenous depression 29.7 BDNF CRH CRHR1 HTR1A HTR2A MAOA
48 paranoid schizophrenia 29.6 BDNF COMT HTR2A MAOA SLC6A4 TPH2
49 early-onset schizophrenia 29.5 BDNF HTR2A
50 amnestic disorder 29.5 BDNF CNR1 HTR1A

Comorbidity relations with Anxiety via Phenotypic Disease Network (PDN): (show top 50) (show all 80)


Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Borderline Personality Disorder
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Rhinitis Conn's Syndrome
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hyperlipoproteinemia, Type Iv Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Labyrinthitis
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Migraine with or Without Aura 1
Mitral Valve Disease Mood Disorder

Graphical network of the top 20 diseases related to Anxiety:



Diseases related to Anxiety

Symptoms & Phenotypes for Anxiety

Clinical features from OMIM:

607834

UMLS symptoms related to Anxiety:


agitation, nervousness, sleeplessness, mental and behavioral signs and symptoms, feeling tense, feeling jittery, anxiety symptoms

MGI Mouse Phenotypes related to Anxiety:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 BDNF CCKBR CNR1 COMT CRH CRHR1
2 homeostasis/metabolism MP:0005376 10.13 BDNF CCKBR CNR1 COMT CRH CRHR1
3 cardiovascular system MP:0005385 10.07 CCKBR COMT CRHR1 HTR1A MAOA NR3C1
4 nervous system MP:0003631 9.97 BDNF CCKBR CNR1 COMT CRH CRHR1
5 adipose tissue MP:0005375 9.91 CNR1 CRH HTR2C NR3C1 TPH1 TPH2
6 integument MP:0010771 9.91 BDNF CCKBR CNR1 CRH HTR2C NR3C1
7 no phenotypic analysis MP:0003012 9.5 BDNF CNR1 CRH CRHR1 HTR1A NR3C1
8 respiratory system MP:0005388 9.23 BDNF COMT CRH CRHR1 NR3C1 PTK7

Drugs & Therapeutics for Anxiety

Drugs for Anxiety (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1267)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 28981-97-7 2118
2
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 99-66-1 3121
3
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
4
Vortioxetine Approved, Investigational Phase 4,Phase 3,Phase 2 508233-74-7 9966051
5
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10024-97-2 948
6
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
7
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
8
Buspirone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36505-84-7 2477
9
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
10
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59467-70-8 4192
11
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
12
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 57-27-2 5288826
13
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
14
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
15
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
16
Rocuronium Approved Phase 4,Phase 3,Not Applicable 119302-91-9, 143558-00-3 441290
17
Etomidate Approved Phase 4,Not Applicable 33125-97-2 667484 36339
18
Sufentanil Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56030-54-7 41693
19 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 27203-92-5 33741
21
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
22
Trimebutine Approved Phase 4 39133-31-8
23
Rabeprazole Approved, Investigational Phase 4,Not Applicable 117976-89-3 5029
24
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 439-14-5 3016
25
Amoxicillin Approved, Vet_approved Phase 4,Early Phase 1 26787-78-0 33613
26
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1972-08-3 16078
27
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
28
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 616-91-1 12035
29
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
30
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 28014-46-2
31
Drospirenone Approved Phase 4 67392-87-4 68873
32
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-28-2 5757
33 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 979-32-8
34
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
35
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 113-45-1 4158
36
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
37
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
38
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
39
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 56-12-2 119
40
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 60142-96-3 3446
41
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 54739-18-3 3404 5324346
42
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 24219-97-4 4184
43
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
44
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
45
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61337-67-5, 85650-52-8 4205
46
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
47
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 298-46-4 2554
48
Oxcarbazepine Approved Phase 4,Phase 3 28721-07-5 34312
49
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
50
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder Unknown status NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
2 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
3 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
4 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
5 The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung Unknown status NCT01362114 Phase 4 SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
6 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
7 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
8 Preoperative Anxiety and Postoperative Pain in Children Unknown status NCT00643032 Phase 4
9 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
10 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
11 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial Unknown status NCT02243826 Phase 4 50:50 mixture of nitrous oxide/oxygen
12 A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children Unknown status NCT02459509 Phase 4 Dexmedetomidine
13 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
14 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
15 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
16 Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD) Unknown status NCT01990937 Phase 4 Oral midazolam
17 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4 Lorazepam;Control
18 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
19 MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial) Unknown status NCT02856698 Phase 4 Midazolam;Morphine
20 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
21 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
22 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
23 Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients Unknown status NCT02134093 Phase 4 Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium;Dexmedetomidine;Normal saline;Maintenance of anesthesia , propofol, remifentanil,vecuronium
24 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
25 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
26 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
27 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
28 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
29 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
30 Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis Unknown status NCT00730834 Phase 4
31 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4 Diazepam
32 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
33 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
34 Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia Unknown status NCT02258763 Phase 4 Amoxicillin-Potassium Clavulanate Combination;Placebo
35 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
36 Impact of Probiotic Preparation VSL#3 on Infants Colics Unknown status NCT01869426 Phase 4
37 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
38 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
39 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Unknown status NCT00866866 Phase 4 N-Acetyl Cysteine;Placebo
40 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
41 Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement Unknown status NCT00617500 Phase 4 Hormones
42 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
43 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
44 Pregabalin for Alcohol Dependence Unknown status NCT02205879 Phase 4 Pregabalin;Placebo
45 Ultrasound Guided Cannulation of Dialysis Fistulas Unknown status NCT01163981 Phase 4
46 Paracervical Block for Pain Control in First Trimester Abortion Unknown status NCT01094366 Phase 4
47 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
48 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
49 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
50 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR

Search NIH Clinical Center for Anxiety

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: anxiety disorders

Genetic Tests for Anxiety

Genetic tests related to Anxiety:

# Genetic test Affiliating Genes
1 Anxiety 29

Anatomical Context for Anxiety

MalaCards organs/tissues related to Anxiety:

41
Brain, Breast, Testes, Heart, Prostate, Lung, Amygdala

Publications for Anxiety

Articles related to Anxiety:

(show top 50) (show all 9211)
# Title Authors Year
1
Parental anxiety towards 'refer' results in newborn hearing screening (NHS) in south India: A hospital based study. ( 30554702 )
2019
2
Corrigendum to "The development and validation of Huaxi emotional-distress index (HEI): A Chinese questionnaire for screening depression and anxiety in non-psychiatric clinical settings" [Compr. Psychiatry 76 (2017) 87-97]. ( 30501894 )
2019
3
Anxiety and risk of dementia: Systematic review and meta-analysis of prospective cohort studies. ( 30502746 )
2019
4
The Elevated Plus Maze Test for Measuring Anxiety-Like Behavior in Rodents. ( 30535682 )
2019
5
The Open Field Test for Measuring Locomotor Activity and Anxiety-Like Behavior. ( 30535687 )
2019
6
Substance use outcomes in cocaine-dependent tobacco smokers: A mediation analysis exploring the role of sleep disturbance, craving, anxiety, and depression. ( 30466549 )
2019
7
Predicting treatment outcome for anxiety disorders with or without comorbid depression using clinical, imaging and (epi)genetic data. ( 30480619 )
2019
8
Adverse effects of anxiety on attentional control differ as a function of experience: A simulated driving study. ( 30487108 )
2019
9
Problematic attention processing and fear learning in adolescent anxiety: Testing a combined cognitive and learning processes model. ( 30412825 )
2019
10
Salivary testosterone concentration, anxiety, perceived performance and ratings of perceived exertion in basketball players during semi-final and final matches. ( 30365978 )
2019
11
Exposure to nanoscale diesel exhaust particles: Oxidative stress, neuroinflammation, anxiety and depression on adult male mice. ( 30391838 )
2019
12
Assessment of anxiety and stress markers in children submitted to educational strategies and ART-restoration: A randomized clinical trial. ( 30396037 )
2019
13
Improved cognition, mild anxiety-like behavior and decreased motor performance in pyridoxal phosphatase-deficient mice. ( 30327125 )
2019
14
Effect of fluoride exposure on anxiety- and depression-like behavior in mouse. ( 30336322 )
2019
15
Prevalence of and factors contributing to anxiety, depression and cognitive disorders among urban elderly in Odisha - A study through the health systems' Lens. ( 30336373 )
2019
16
miR-132/212 is induced by stress and its dysregulation triggers anxiety-related behavior. ( 30342060 )
2019
17
Imagery-based treatment for test anxiety: A multiple-baseline open trial. ( 30343122 )
2019
18
Relations between trait anxiety and depression: A mediated moderation model. ( 30359817 )
2019
19
Evaluating the role of mindfulness in terms of asthma-related outcomes and depression and anxiety symptoms among individuals with asthma. ( 30286606 )
2019
20
Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. ( 30292023 )
2019
21
Symptoms of social anxiety disorder and major depressive disorder: A network perspective. ( 30292147 )
2019
22
Cooperation of the vestibular and cerebellar networks in anxiety disorders and depression. ( 30292730 )
2019
23
A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris. ( 30293440 )
2019
24
Social anxiety and employment interviews: does nonverbal feedback differentially predict cortisol and performance? ( 30298757 )
2019
25
Anxiety and depression among adult amputees: the role of attachment insecurity, coping strategies and social support. ( 30299156 )
2019
26
Appraisals of dependent stressor controllability and severity are associated with depression and anxiety symptoms in youth. ( 30303017 )
2019
27
Anatomical prosection practices in the Occupational Therapy degree. Student anxiety levels and academic effectiveness. ( 30315912 )
2019
28
Interrelationships among depression, anxiety, flourishing, and cannabis use in youth. ( 30321693 )
2019
29
Maternal suppplementation with conjugated linoleic acid reduce anxiety and lipid peroxidation in the offspring brain. ( 30236761 )
2019
30
The effects of childhood maltreatment and anxiety proneness on neuropsychological test performance in non-clinical older adolescents. ( 30243193 )
2019
31
Measurement equivalence of the Social Interaction Anxiety Scale (SIAS) and Social Phobia Scale (SPS) across individuals with social anxiety disorder from Japanese and Australian sociocultural contexts. ( 30243196 )
2019
32
Altered temporal variance and functional connectivity of BOLD signal is associated with state anxiety during acute systemic inflammation. ( 30243957 )
2019
33
Pregnancy anxiety predicts shorter gestation in Latina and non-Latina white women: The role of placental corticotrophin-releasing hormone. ( 30245329 )
2019
34
Neuroticism and extraversion mediate the relationship between having a sibling with developmental disabilities and anxiety and depression symptoms. ( 30248634 )
2019
35
Affective models of depression and anxiety: Extension to within-person processes in daily life. ( 30248635 )
2019
36
Persistent depressive disorder has long-term negative impacts on depression, anxiety, and somatic symptoms at 10-year follow-up among patients with major depressive disorder. ( 30248637 )
2019
37
Maternal pre- and postnatal anxiety symptoms and infant attention disengagement from emotional faces. ( 30253357 )
2019
38
Stress experience and performance during an oral exam: the role of self-efficacy, threat appraisals, anxiety, and cortisol. ( 30257566 )
2019
39
Prevalence, risk factors and multi-group latent class analysis of lifetime anxiety disorders comorbid depressive symptoms. ( 30266027 )
2019
40
A randomized controlled trial of 'MUMentum Pregnancy': Internet-delivered cognitive behavioral therapy program for antenatal anxiety and depression. ( 30266030 )
2019
41
Psychosocial factors associated with symptoms of depression, anxiety and stress among single mothers with young children: A population-based study. ( 30218920 )
2019
42
Probiotics modify body weight together with anxiety states via pro-inflammatory factors in HFD-treated Syrian golden hamster. ( 30223002 )
2019
43
High risk of depression, anxiety, and poor quality of life among experienced fathers, but not mothers: A prospective longitudinal study. ( 30170237 )
2019
44
Sedentary behaviour and risk of anxiety: A systematic review and meta-analysis. ( 30170238 )
2019
45
Neural connectivity during affect labeling predicts treatment response to psychological therapies for social anxiety disorder. ( 30173058 )
2019
46
The moderating role of social support for marital adjustment, depression, anxiety, and stress: Evidence from Pakistani working and nonworking women. ( 30173879 )
2019
47
Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression? ( 30176494 )
2019
48
Can chronotype function as predictor of a persistent course of depressive and anxiety disorder? ( 30179789 )
2019
49
Corrigendum to "Taxonicity and network structure of generalized anxiety disorder and major depressive disorder: An admixture analysis and complex network analysis." [Journal of Affective Disorders, 199 (2016) 99-105]. ( 30189353 )
2019
50
Social anxiety and drinking game behaviors among Australian university students. ( 30138776 )
2019

Variations for Anxiety

ClinVar genetic disease variations for Anxiety:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HMBS NM_000190.3(HMBS): c.958delG (p.Ala320Leufs) deletion Likely pathogenic rs1057518806 GRCh37 Chromosome 11, 118963865: 118963865
2 HMBS NM_000190.3(HMBS): c.958delG (p.Ala320Leufs) deletion Likely pathogenic rs1057518806 GRCh38 Chromosome 11, 119093155: 119093155
3 OTX2 NM_172337.2(OTX2): c.167_169delTGTinsGG (p.Leu56Argfs) indel Likely pathogenic GRCh38 Chromosome 14, 56804268: 56804270
4 OTX2 NM_172337.2(OTX2): c.167_169delTGTinsGG (p.Leu56Argfs) indel Likely pathogenic GRCh37 Chromosome 14, 57270986: 57270988

Copy number variations for Anxiety from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139649 2 185171337 185512459 Deletion ZNF804A anxiety disorder

Expression for Anxiety

Search GEO for disease gene expression data for Anxiety.

Pathways for Anxiety

Pathways related to Anxiety according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 CCKBR CNR1 CRH CRHR1 HTR1A HTR2A
2
Show member pathways
12.87 BDNF CNR1 CRH CRHR1 HTR2A HTR2C
3 12.41 CNR1 COMT HTR1A TPH1 TPH2
4
Show member pathways
12.04 CYP3A4 MAOA TPH1 TPH2
6 11.97 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
7
Show member pathways
11.83 HTR1A HTR2A HTR2C
8 11.77 CCKBR CNR1 HTR2A
9 11.62 CYP2D6 HTR1A HTR2A HTR2C MAOA SLC6A4
10
Show member pathways
11.52 COMT CYP2D6 CYP3A4
11
Show member pathways
11.42 COMT CYP2D6 CYP3A4 SLC6A4
12
Show member pathways
11.27 MAOA SLC6A4 TPH2
13
Show member pathways
11 COMT MAOA SLC6A4
14 10.9 HTR2A HTR2C
15
Show member pathways
10.89 COMT MAOA TPH1
16
Show member pathways
10.75 COMT MAOA
17
Show member pathways
10.74 CYP2D6 CYP3A4
18 10.7 COMT MAOA
19 10.66 CCKBR CNR1
20 10.61 HTR1A HTR2A HTR2C MAOA SLC6A4 TPH1
21 10.36 CRH CRHR1

GO Terms for Anxiety

Cellular components related to Anxiety according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 CNR1 CRHR1 HTR1A HTR2A HTR2C PTK7
2 dendrite GO:0030425 9.35 BDNF COMT HTR1A HTR2A HTR2C
3 integral component of presynaptic membrane GO:0099056 8.8 CNR1 HTR2A SLC6A4

Biological processes related to Anxiety according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.93 CRH HTR1A HTR2A HTR2C
2 response to drug GO:0042493 9.89 COMT CRH HTR2A HTR2C SLC6A4
3 steroid metabolic process GO:0008202 9.82 CRH CYP2D6 CYP3A4
4 female pregnancy GO:0007565 9.81 COMT CRH CRHR1
5 circadian rhythm GO:0007623 9.81 SLC6A4 TPH1 TPH2
6 response to estrogen GO:0043627 9.77 COMT CRH TPH2
7 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.74 CCKBR HTR2A HTR2C
8 positive regulation of fat cell differentiation GO:0045600 9.71 HTR2A HTR2C TPH1
9 long-chain fatty acid biosynthetic process GO:0042759 9.65 CYP2D6 CYP3A4
10 response to pain GO:0048265 9.65 COMT CRH
11 vasoconstriction GO:0042310 9.64 HTR1A SLC6A4
12 parturition GO:0007567 9.62 CRH CRHR1
13 catecholamine metabolic process GO:0006584 9.62 COMT MAOA
14 neurotransmitter catabolic process GO:0042135 9.61 COMT MAOA
15 aromatic amino acid family metabolic process GO:0009072 9.61 TPH1 TPH2
16 oxidative demethylation GO:0070989 9.6 CYP2D6 CYP3A4
17 dopamine catabolic process GO:0042420 9.58 COMT MAOA
18 heterocycle metabolic process GO:0046483 9.58 CYP2D6 CYP3A4
19 drug catabolic process GO:0042737 9.56 CYP2D6 CYP3A4
20 memory GO:0007613 9.56 BDNF CNR1 HTR2A SLC6A4
21 monoterpenoid metabolic process GO:0016098 9.55 CYP2D6 CYP3A4
22 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.52 HTR2A HTR2C
23 alkaloid catabolic process GO:0009822 9.48 CYP2D6 CYP3A4
24 positive regulation of circadian sleep/wake cycle, wakefulness GO:0010841 9.46 CRH NPS
25 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.46 CNR1 HTR1A HTR2A HTR2C
26 serotonin biosynthetic process GO:0042427 9.43 TPH1 TPH2
27 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.37 HTR2A HTR2C
28 regulation of serotonin secretion GO:0014062 9.32 CRH HTR1A
29 behavior GO:0007610 9.13 HTR1A HTR2A HTR2C
30 serotonin receptor signaling pathway GO:0007210 8.8 HTR1A HTR2A HTR2C